Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

28th Oct 2015 16:20

SHIRE PLC - Director/PDMR Shareholding

SHIRE PLC - Director/PDMR Shareholding

PR Newswire

London, October 28

Director/PDMR Share Dealings

October 28, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that deferred American Depositary Shares (“ADSs”) granted to Phil Vickers, a Person Discharging Managerial Responsibilities, were automatically released today in accordance with the terms of a deferred share award granted on November 11, 2013. One ADS is equal to three Ordinary shares of 5 pence each in the Company.

The number of ADSs released and the number that lapsed are as follows:

ADSs Released(1)ADSs Lapsed(2)
493442

(1) In accordance with the terms of the deferred share award, the vested deferred ADSs were increased by an amount equivalent, at the date of vesting, to the value of dividends paid by the Company in respect of the deferred ADSs from the date of grant to the date of vesting.

(2) The number of ADSs lapsed is equivalent in value to Mr. Vickers’ tax liability resulting from the release of the deferred ADSs.

No amount was payable by Mr. Vickers in respect of the release of the deferred ADSs.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Oliver StrawbridgeSenior Assistant Company Secretary

For further information please contact:

Investor Relations
Matthew Osborne[email protected]+1 781 482 9502
Sarah Elton-Farr[email protected]+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

http://www.shire.com/


Related Shares:

Shire
FTSE 100 Latest
Value8,602.92
Change0.00